The three types of genes that play a role in cancer are oncogenes, tumor suppressor genes, and DNA repair genes. Each type normally performs a specific job in controlling how cells grow, divide, and fix themselves. Cancer develops when mutations in one or more of these gene types disrupt that balance, allowing cells to multiply without the usual checks in place.
Oncogenes: A Stuck Gas Pedal
Every cell in your body contains proto-oncogenes, which are normal genes that help cells grow, divide, and survive. They’re essential. The problem starts when a proto-oncogene picks up a mutation or gets copied too many times, turning it into an oncogene. Think of it as a gas pedal that gets jammed down: the cell receives a constant “grow” signal even when it shouldn’t.
Oncogenes are dominant, meaning a mutation in just one copy of the gene is enough to cause trouble. The mutated gene produces too much of a growth-promoting protein, or produces a version of that protein that’s permanently switched on. The result is increased cell division, a loss of the normal process where cells mature and specialize, and resistance to the programmed cell death that usually eliminates damaged cells. Together, those traits are what define a cancer cell.
Some well-known oncogenes include RAS (mutated in a wide range of cancers) and HER2 (linked to aggressive forms of breast cancer). In each case, the original proto-oncogene had a perfectly healthy function before a mutation flipped it into overdrive.
Tumor Suppressor Genes: Missing Brakes
If oncogenes are a stuck gas pedal, tumor suppressor genes are the brakes. They slow down cell division, trigger repair when DNA is damaged, and tell cells to self-destruct when damage is too severe to fix. When these genes stop working, cells lose their ability to halt growth or eliminate themselves, and abnormal cells can accumulate.
The most important tumor suppressor gene is p53, sometimes called “the guardian of the genome.” When a cell experiences stress or DNA damage, p53 can pause the cell cycle so repairs can happen, push the cell into permanent retirement so it never divides again, or activate programmed cell death to remove the damaged cell entirely. Mutations in p53 don’t just remove this protective function. Some p53 mutations produce a defective protein that actively interferes with any remaining normal copies, essentially poisoning the whole system from within.
Unlike oncogenes, tumor suppressor genes typically require both copies to be knocked out before cancer develops. You inherit one copy from each parent. A concept known as the “two-hit hypothesis,” proposed by researcher Alfred Knudson, explains why: losing just one copy still leaves a functional backup. The second copy has to be lost or silenced before the braking system fails completely. In hereditary cancers, a person is born with one defective copy already in place, so only one additional mutation is needed. In non-hereditary (sporadic) cancers, both hits occur randomly over a lifetime, which is one reason why cancer becomes more common with age.
DNA Repair Genes: The Maintenance Crew
Your DNA sustains thousands of small injuries every day from normal metabolism, sunlight, and environmental exposures. DNA repair genes encode the proteins that find and fix those errors. When repair genes themselves are mutated, damage in other genes goes uncorrected, and mutations pile up across the genome. This can eventually hit proto-oncogenes or tumor suppressor genes, setting the stage for cancer through a chain reaction of accumulating errors.
The best-known DNA repair genes are BRCA1 and BRCA2. These genes are central to a specific repair process that fixes double-strand breaks, one of the most dangerous types of DNA damage. When BRCA1 or BRCA2 isn’t functioning properly, cells lose access to this high-fidelity repair pathway and become dependent on less reliable backup methods, allowing mutations to accumulate faster.
Roughly 10 to 15 percent of patients with ovarian, breast, pancreatic, and prostate cancers carry inherited BRCA1 or BRCA2 mutations. Another 15 to 30 percent have mutations in BRCA-related genes that arose during their lifetime rather than being inherited. Targeted therapies now exist that exploit the specific weakness these mutations create: because BRCA-deficient cancer cells rely on an alternative repair mechanism to survive, drugs that block that alternative pathway can selectively kill those cancer cells while leaving healthy cells largely intact.
How These Gene Types Work Together
Cancer rarely results from a single mutation in a single gene. It’s typically a multi-step process. A cell might first lose one copy of a tumor suppressor gene, then decades later lose the second copy, then pick up an activating mutation in a proto-oncogene. Or a DNA repair gene fails first, which accelerates the rate at which mutations accumulate in the other two categories. The order varies, but the endpoint is the same: a cell that grows without restraint, ignores stop signals, and can’t fix its own errors.
Not every mutation matters equally. Researchers distinguish between “driver” mutations and “passenger” mutations. Driver mutations give a cell a real growth advantage and actively push it toward becoming cancerous. Passenger mutations are random changes that happen to be present in a cancer cell but don’t contribute to the disease. When the same gene turns up mutated across many different patients, that’s strong evidence it’s a driver. The Cancer Gene Census, maintained by the Wellcome Sanger Institute, catalogs hundreds of confirmed driver genes across all human cancer types.
Understanding which category a gene falls into, whether it’s an oncogene, tumor suppressor, or DNA repair gene, shapes how doctors approach treatment. A cancer driven by an overactive oncogene may respond to drugs that block the specific protein it produces. A cancer caused by BRCA mutations may respond to therapies designed to exploit the broken repair pathway. The three-category framework isn’t just a textbook concept. It’s the foundation of modern precision oncology.